Literature DB >> 25662489

A high-efficiency, low-toxicity, phospholipids-based phase separation gel for long-term delivery of peptides.

Ting Zhang1, Qiang Peng1, Feng-Ying San1, Jing-Wen Luo1, Meng-Xin Wang1, Wen-Qi Wu1, Tao Gong2, Zhi-Rong Zhang3.   

Abstract

Peptide and protein drugs are currently under rapid development attributed to their high potency and efficacy in therapy. Their successful delivery, however, is highly limited by their short half-life, fast degradation and rapid clearance. Here, we present a high content phospholipids-based phase separation gel (PPSG), which is readily injectable due to its low initial viscosity and can rapidly transform into an in situ implant after injection upon exposure to an aqueous environment. A selected model peptide, octreotide acetate, is loaded into PPSG and achieves sustained release profiles for one month in rats. In addition, the local irritation caused by ethanol contained in PPSG is ethanol content-dependent and the irritation of PPSG with 70% phospholipids content can be eliminated by partially replacing ethanol with medium chain triglyceride. The mechanisms underlying phase transition of PPSG are based on water-insolubility of phospholipids. Our findings demonstrate that PPSG is a readily injectable, highly safe and efficient in situ forming implant for sustained delivery of peptides.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drug delivery; Gel; Implant; Irritation; Long-term release; Phospholipid

Mesh:

Substances:

Year:  2015        PMID: 25662489     DOI: 10.1016/j.biomaterials.2014.12.042

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  7 in total

1.  Thymopentin-loaded phospholipid-based phase separation gel with long-lasting immunomodulatory effects: in vitro and in vivo studies.

Authors:  Ting Zhang; Xian-Yan Qin; Xi Cao; Wen-Hao Li; Tao Gong; Zhi-Rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2018-07-12       Impact factor: 6.150

2.  Long-Acting Phospholipid Gel of Exenatide for Long-Term Therapy of Type II Diabetes.

Authors:  Mei Hu; Yu Zhang; Nanxi Xiang; Ying Zhong; Tao Gong; Zhi-Rong Zhang; Yao Fu
Journal:  Pharm Res       Date:  2016-02-08       Impact factor: 4.200

Review 3.  Fundamental Aspects of Lipid-Based Excipients in Lipid-Based Product Development.

Authors:  Deepa Nakmode; Valamla Bhavana; Pradip Thakor; Jitender Madan; Pankaj Kumar Singh; Shashi Bala Singh; Jessica M Rosenholm; Kuldeep K Bansal; Neelesh Kumar Mehra
Journal:  Pharmaceutics       Date:  2022-04-11       Impact factor: 6.525

4.  Curcumin- and Cyclopamine-Loaded Liposomes to Enhance Therapeutic Efficacy Against Hepatic Fibrosis.

Authors:  Ting Zhang; Yanping Li; Yi Song; Xiaoshuang Chen; Jing Li; Qiang Peng; Jinhan He; Xiaofan Fei
Journal:  Drug Des Devel Ther       Date:  2020-12-23       Impact factor: 4.162

5.  Preparation and evaluation of a phospholipid-based injectable gel for the long term delivery of leuprolide acetaterrh.

Authors:  Danhong Long; Tao Gong; Zhirong Zhang; Rui Ding; Yao Fu
Journal:  Acta Pharm Sin B       Date:  2016-06-16       Impact factor: 11.413

6.  Parenteral Sustained Release Lipid Phase-Transition System of Ziprasidone: Fabrication and Evaluation for Schizophrenia Therapy.

Authors:  Urooj A Khan; Uzma Parveen; Nazeer Hasan; Mohammad Zubair Ahmed; Suma Saad; Farhan J Ahmad; Gaurav K Jain
Journal:  Drug Des Devel Ther       Date:  2020-06-09       Impact factor: 4.162

7.  pH-Responsive Polyethylene Glycol Monomethyl Ether-ε-Polylysine-G-Poly (Lactic Acid)-Based Nanoparticles as Protein Delivery Systems.

Authors:  Huiqin Liu; Yijia Li; Rui Yang; Xiujun Gao; Guoguang Ying
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.